China NMPA Approves Phase III Clinical Trial of ASC40 Combined with Bevacizumab for Treatment of Patients with Recurrent Glioblastoma,

HANGZHOU, China and SHAOXING, China, July 21, 2021 /PRNewswire/ — Ascletis Pharma Inc. (HKEX code: 1672) today announces that China National Medical Products Administration (NMPA) has approved the …, HANGZHOU, China and SHAOXING, China, July 21, 2021 /PRNewswire/ — Ascletis Pharma Inc. (HKEX code: 1672) today announces that China National Medical Products Administration (NMPA) has approved the …, Read More

Scroll to Top